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ABSTRACT 
 
Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant 
MET expression is prevalent in mesothelioma, although targeting using small molecule-based 
therapeutics has proven disappointing. Chimeric antigen receptors (CARs) couple the HLA-
independent binding of a cell surface target to the delivery of a tailored T-cell activating 
signal. Here, we evaluated the anti-tumor activity of MET re-targeted CAR T-cells against 
mesothelioma. Using immunohistochemistry, MET was detected in 67% of malignant pleural 
mesotheliomas, most frequently of epithelioid or biphasic subtype. The presence of MET did 
not influence patient survival. Candidate MET-specific CARs were engineered in which a 
CD28+CD3ζ endodomain was fused to one of three peptides derived from the N and K1 
domains of hepatocyte growth factor (HGF), which represents the minimum MET binding 
element present in this growth factor. Using an NIH3T3-based artificial antigen-presenting 
cell system, we found that all three candidate CARs demonstrated high specificity for MET. 
By contrast, these CARs did not mediate T-cell activation upon engagement of other HGF 
binding partners, namely CD44v6 or heparan sulfate proteoglycans, including Syndecan-1. 
NK1-targeted CARs demonstrated broadly similar in vitro potency, indicated by destruction 
of MET-expressing mesothelioma cell lines, accompanied by cytokine release. In vivo anti-
tumor activity was demonstrated following intraperitoneal delivery to mice with an 
established mesothelioma xenograft. Progressive tumor regression occurred without weight 
loss or other clinical indicators of toxicity. These data confirm the frequent expression of 
MET in malignant pleural mesothelioma and demonstrate that this can be targeted effectively 
and safely using a CAR T-cell immunotherapeutic strategy. 
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INTRODUCTION 
 
Mesothelioma derives from malignant transformation of mesothelial cells that line body 
cavities. Tumors most commonly originate from the pleural space and are primarily attributed 
to inhalation of asbestos fibers, followed by a prolonged latency period. Despite advances in 
surgical and radiation-based approaches and the advent of pemetrexed-based chemotherapy 
regimens, mesothelioma remains incurable. Furthermore, incidence continues to increase 
worldwide,1 highlighting the need for improved treatments for this intractable cancer.  
 Conceptually, immunotherapy represents an attractive therapeutic approach for 
mesothelioma, given the close inter-relationship between this cancer and the immune 
system.2 Immune checkpoint blockade has elicited promising, albeit somewhat inconsistent 
results in early phase clinical trials.3, 4 An alternative strategy that achieves striking potency 
against some hematologic malignancies entails adoptive immunotherapy using chimeric 
antigen receptor (CAR)-engineered T-cells. Chimeric antigen receptors are fusion molecules 
that couple the binding of a native cell surface target to the delivery of a bespoke T-cell 
activating signal.5 Pre-clinical studies using a number of mesothelioma models have 
demonstrated efficacy of CAR T-cells directed against mesothelin6, 7 and fibroblast-activation 
protein.8, 9 Clinical trials of intrapleural10, 11 or intravenously administered CAR T-cell 
immunotherapy12 are currently ongoing in patients with this cancer.  
A number of pivotal receptor tyrosine kinases are commonly dysregulated in 
mesothelioma.13 These also represent attractive targets for CAR-based immunotherapy, given 
their contribution to disease pathogenesis and the potential for regional delivery of 
engineered T-cells as a device to maximize therapeutic index.14 In keeping with this, we have 
recently demonstrated that ErbB re-targeted CAR T-cells achieve significant anti-tumor 
activity combined with excellent safety in pre-clinical models of malignant pleural 
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mesothelioma (MPM).15 The MET receptor tyrosine kinase is also aberrantly expressed in a 
large proportion of mesotheliomas16-21 and has been proposed as an attractive therapeutic 
target in this disease.18, 22, 23 Disappointingly however, a phase II trial of the selective MET 
inhibitor tivantinib has recently been terminated 
(https://clinicaltrials.gov/ct2/show/NCT01861301; accessed March 25th, 2017). 
Consequently, more potent MET-targeted approaches such as CAR T-cell immunotherapy 
warrant investigation in this disease. 
Hepatocyte growth factor (HGF; also known as scatter factor) is the only known MET 
ligand. It has a plasminogen-like structure that comprises an N-terminal and four Kringle (K) 
domains, followed by a catalytically inactive serine proteinase module. The shortest naturally 
occurring splice variant of HGF, named NK1, comprises the N and K1 domains alone.24 
Initially described as a MET antagonist,25 conditional agonistic activity has more recently 
been attributed to NK1.26 This requires binding of a glycosaminoglycan (GAG) such as 
heparan sulfate27 (or soluble heparin), which promotes NK1 dimerization and also facilitates 
the formation of a ternary complex with NK1 and MET.28   
Given these binding properties, we have evaluated NK1 as a targeting moiety to 
generate a MET-specific CAR. Three variants of NK1 have been compared in which 
functional activity or stability have been enhanced by protein engineering. We report here 
that all three CAR candidates mediate MET-dependent T-cell activation and destruction of 
mesothelioma cells. Moreover, adoptive immunotherapy using MET re-targeted CAR T-cells 
promotes tumor regression in a mesothelioma xenograft model, without toxicity. 
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RESULTS 
 
Expression of MET by malignant pleural mesotheliomas 
To characterise MET receptor expression, tissue microarrays were prepared from 114 MPMs 
of epithelioid (59.8%), sarcomatoid (22.0%) or biphasic (18.3%) morphology (histologic 
subtype available for 82 tumors).  There was a small but insignificant trend for improved 
survival in patients with epithelioid subtype tumors (Fig. 1A). Analysis of a larger series of 
MPM that contained the subset presented here confirmed, as expected, that epithelioid tumors 
were associated with improved patient survival.15 
 Expression of MET was detected by immunohistochemistry in 67.6% of MPM, either 
at low (28.1%), intermediate (24.6%) or high intensity (14.9%). Receptor distribution was 
cytoplasmic with membranous accentuation (Fig. 1B). MET expression was more frequent in 
epithelioid (71.4%) and biphasic tumors (66.7%), although it was also commonly found in 
sarcomatoid tumors (44.4%). All tumors in which MET expression was of high intensity 
were of epithelioid or biphasic subtypes.  Neither the presence, nor the intensity of MET 
expression was associated with alteration in patient survival (Fig. 1C). 
 
Engineering of candidate MET-specific chimeric antigen receptors 
To exploit the frequent expression of MET in MPM, we set out to engineer a CAR that 
targets this receptor. Three derivatives of the NK1 splice variant of HGF were evaluated for 
their ability to re-target a second generation (CD28+CD3z)29 CAR specifically against MET. 
In 1K1,28 two basic amino acids within the low affinity heparan-binding region of the K1 
domain have been replaced with acidic residues, yielding a variant with enhanced MET 
agonistic properties (Fig. 2A). The M2.2 variant was isolated using a mutagenesis approach 
and contains 8 alterations distributed across the N and K1 domains, one of which has been 
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reverted (D127N) to restore MET agonistic activity (M2.2rev).30 M2.2rev exhibits enhanced 
stability as does the cysteine-containing M2.2 D127N variant (cM2.2rev; Fig. 2A).30 All 
three were placed downstream of the HGF signal peptide and were coupled to a previously 
described CD28+CD3z second generation CAR framework29 in which a Myc epitope tag had 
been substituted for the MYPPPY motif within the CD28 ectodomain (Fig. 2B).31 The 
resultant CARs, named 1-28z, M-28z and cM-28z respectively, were expressed in human T-
cells by retroviral-mediated gene transfer. Comparison was made with a pan-ErbB targeted 
CAR (T-28z, targeted with a promiscuous ErbB ligand named T1E)32 and a negative control 
in which the targeting moiety consisted of a scrambled 20mer peptide sequence (C-28z).31 
Since all CARs contain a Myc epitope tag, cell surface expression was compared by flow 
cytometry after incubation of transduced cells with the 9e10 antibody (Fig. 2C). Stable 
expression of candidate MET-specific CARs was also confirmed in human T-cells by 
western blotting (Fig. 2D). In some experiments, CARs were co-expressed with a chimeric 
cytokine receptor named 4ab in which IL-4 receptor a ectodomain has been fused to the 
transmembrane and endodomain of the IL-2/15 receptor b chain (Fig. S1). Culture of 4ab-
expressing CAR T-cells in IL-4 leads to selective enrichment of transduced cells, with 
retention of type 1 polarity,31-33 providing a convenient device to enrich for transduced T-
cells during in vitro expansion.  
 
Characterisation of specificity of candidate CARs using NIH3T3 artificial antigen 
presenting cells 
In many settings, HGF-dependent activation of MET is dependent on the co-expression of 
CD44v6, which are non-heparin/heparan sulfated isoforms of CD44 that bind HGF with 
micromolar affinity.34 Hepatocyte growth factor has also been reported to bind to GAGs and 
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proteoglycans. Notable examples include heparan sulfate proteoglycans (HSPG),35 such as 
Syndecan-1.36  
To investigate the target specificity of the candidate MET CARs described above, 
artificial antigen-presenting cells (AAPC) were engineered whereby NIH3T3 mouse 
fibroblasts were modified to express human MET, CD44v6 or both of these molecules (Fig. 
3A).37 T-cells were engineered to express candidate MET-specific (1-28z, M-28z, cM-28z), 
the C-28z control CAR or T-28z, which targets ErbB dimers (absent in NIH3T3 cells) (Fig. 
3B). We observed that 1-28z+, M-28z+ and cM-28z+ human T-cells elicited comparable 
killing of MET-expressing NIH3T3 cells, in a dose- and time-dependent manner (Fig. 3C). 
Activation of MET re-targeted CAR T-cells was accompanied by secretion of low levels of 
interferon (IFN)-g (Fig. 3D). As expected, ErbB-specific (T-28z) and control (C-28z) CAR 
T-cells were inactive in these assays. Co-expression of CD44v6 was not required for 
cytotoxicity or cytokine release, although there was a significant increase in IFN-g release by 
MET re-targeted CAR T-cells when CD44v6 and MET were co-expressed (Fig. 3D).  
Although unmodified NIH3T3 cells express HSPG (Fig. S2A),38, 39 they were not 
killed (Fig. 3C) nor did they promote significant IFN-g release (Fig. 3D) by any of the CAR 
T-cell populations under study. To test potential HSPG reactivity more stringently, we 
engineered NIH3T3 cells to over-express the human HSPG, Syndecan-1 (Fig. 4A), which is 
known to bind HGF and is commonly expressed in MPM and derived cell lines (Fig. 5B).40 
When co-cultivated with MET re-targeted CAR T-cells (Fig. 4B), destruction of MET-
expressing, but not Syndecan-1 expressing, NIH3T3 cells was observed (Fig. 4C). Moreover, 
release of IFN-g was only detected when these CAR T-cells were co-cultivated with MET-
expressing but not Syndecan-1 expressing NIH3T3 cells (data not shown). As expected, 
control CAR T-cells were inactive in these assays. 
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MET re-targeted CAR T-cells exert in vitro anti-tumor activity against mesothelioma 
Next, we evaluated anti-tumor activity of MET re-targeted CAR T-cells using a panel of 
human mesothelioma cell lines in which this receptor was naturally expressed, namely H28, 
REN, LO68 and Ju77 (Fig. 5A). All tumor cells co-expressed high levels of HSPGs (Fig. S3), 
generally including Syndecan-1 (Fig. 5B).  
CAR T-cells engineered to express 1-28z, M-28z and cM-28z at comparable, albeit 
lower efficiency (Fig. 6A) mediated equipotent killing of MET-expressing H28 
mesothelioma cells (Fig. 6B). While M-28z+ and cM-28z+ T-cells exerted greater cytotoxic 
activity against REN and LO68 tumor cells (Fig. 6B), this difference was not maintained 
when T-cells were transduced more efficiently (Fig. 7A-B). Tumor cell destruction was 
accompanied by release of IFN-g (Fig. 6C), IL-2 (Fig. S4) and some other cytokines (e.g. IL-
13, GM-CSF; Fig. S5) by MET re-targeted CAR T-cells. Although REN, LO68 and Ju77 
tumor cells proved more resistant to cytotoxic destruction than H28 cells, all three were 
effectively destroyed by MET re-targeted CAR T-cells over a longer time course (Fig. S6). 
Given the variability in tumor cell susceptibility to MET re-targeted CAR T-cells, we 
explored if CD44v6 status might be of relevance in this regard. None of the mesothelioma 
cell lines under study naturally expressed CD44v6 (Fig. 5C). Ectopic over-expression of 
CD44v6 in these tumor cells did not reproducibly influence their susceptibility to cytotoxic 
destruction (Fig. 7B), nor did it lead to significant alteration in the release of IFN-g by 
activated CAR T-cells (Fig. 7C). In these experiments, T-28z represents a positive control, 
given the established ability of ErbB re-targeted CAR T-cells to destroy MPM tumor cells.15 
Moreover, addition of exogenous unfractionated heparin did not influence cytotoxic activity 
of MET re-targeted CAR T-cells against several tumor cell lines (data not shown). In 
summary, these data indicate that MET was both necessary and sufficient for target cell 
engagement and destruction by CAR T-cells containing an NK1-based targeting moiety. 
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Activated T-cells also expressed cell surface HSPGs (Fig. S2B), although they lacked 
expression of Syndecan-1 (Fig. 5B). Furthermore, although MET-expressing T-cell 
populations have been described,41 we did not detect MET expression on the cell surface of 
CAR-engineered T-cells (Fig. 5A), in agreement with previous reports.42 
 
MET re-targeted CAR T-cells exert in vivo anti-tumor activity against an established 
mesothelioma xenograft 
To test in vivo function, an intraperitoneal (i.p.) xenograft model was established in NOD 
SCID gc null mice. REN mesothelioma cells were engineered to co-express tandem dimer 
tomato red fluorescent protein (RFP) and firefly luciferase (ffLuc) and were flow sorted for 
RFP expression (Fig. S7A). Inoculation of 5 – 50 x 104 ffLuc/RFP+ REN cells led to rapid 
tumor engraftment and exponential growth within the peritoneal cavity (Fig. S7B), 
recapitulating the propensity of mesothelioma to undergo intra-cavitary dissemination.  
Given the broadly similar in vitro anti-tumor activity and specificity of all three 
candidate CARs, one (cM-28z) was advanced for in vivo testing. Mice with an established 
ffLuc/RFP+ REN tumor burden were treated i.p. with cM-28z+ T-cells, making comparison 
with C-28z+ (Fig. 8A) or untransduced control T-cells (n=5 each). T-cells were administered 
as a single low (L; 2.5 x 106 cells) or high dose (H; 10 x 106 cells – total T-cell number) and 
tumor status was monitored thereafter by serial bioluminescence imaging. Tumor progression 
in the absence of specific therapeutic intervention was monitored in mice that received PBS 
(n=8). Intraperitoneal administration of a low dose of cM-28z+ T-cells caused a transient and 
minor retardation of tumor progression, followed by sustained disease advancement (Fig. 
8B). By contrast, administration of the higher dose of CAR T-cells led to a progressive and 
significant reduction in tumor burden (Fig. 8C). Bioluminescence images of representative 
animals using the same scale throughout are shown in Fig. 8D. Treatment was extremely well 
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tolerated without weight loss or other clinical indicators of toxicity (Fig. 8E). Furthermore, 
histologic analysis of liver, spleen and intestine harvested from treated animals revealed no 
evidence of pathology (data not shown). Survival analysis was not possible since mice treated 
with T-cells developed signs compatible with graft versus host disease between days 49-69 
(loss of fur, reduced mobility, hunched posture and reduced weight and/or mobility). 
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DISCUSSION 
 
Expression of the MET receptor tyrosine kinase has been reported to occur commonly in 
mesothelioma.16-19 In keeping with this, we detected MET in two thirds of tumors diagnosed 
at our center, with a predilection for epithelioid mesotheliomas. To exploit aberrant MET 
expression in this disease, we set out to engineer a CAR that specifically engages this 
receptor. Targeting was achieved using three derivatives of the smallest natural ligand of the 
MET receptor, namely the NK1 splice variant of HGF. Using an NIH3T3-based AAPC 
system, we demonstrated that all candidate CARs could elicit MET-dependent T-cell 
activation and cytotoxic activity. Similar findings were obtained using a panel of MET-
expressing mesothelioma cell lines. In each case, CAR T-cell effector function was 
dependent upon duration of tumor/ CAR T-cell co-culture. 
In addition to MET, HGF also binds to two discrete co-factor groups, namely CD44v6 
isoforms34 and a range of GAGs and derived proteoglycans.43 Consequently, it was 
imperative to explore whether NK1-based CARs could also engage these molecules, either to 
trigger or to modulate CAR T-cell activation. Using NIH3T3 cells engineered to 
constitutively express human CD44v6, we observed that NK1-based CARs did not mediate 
T-cell activation upon encounter with this potential target in the absence of MET. Moreover, 
T-cell activation was not enhanced in human mesothelioma cells in which CD44v6 was 
ectopically over-expressed. CD44v6 has been reported to bind HGF with micromolar 
affinity.34 However, binding has not been mapped to NK1 and thus insufficient or absent 
engagement of CD44v6 by the targeting moiety may account for these findings. 
Alternatively, the CD44v6 binding epitope on NK1 may be occluded in the CAR format, or 
the binding site may have been altered by one or more of the mutations contained within 
1K1, M2.2rev or cM2.2rev. 
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The question of CAR T-cell binding to GAGs and proteoglycans also requires careful 
consideration. The best characterised binding partners of HGF are heparin, heparan sulfate 
and HSPGs, although weaker binding to other GAGs such as chondroitin sulfate and 
dermatan sulfate has also been reported.44 Interaction between HGF and these GAGs may 
assist in the formation of a ternary complex with MET. The primary binding site for all of 
these GAGs lies within the N domain of HGF,45 an element that is retained in the NK1-based 
CARs tested here. Nonetheless, although unmodified NIH3T3 fibroblasts naturally express 
large quantities of cell surface HSPG,38 these cells did not trigger the activation of any CAR 
under study. One concern is the possibility that mouse-derived NIH3T3 cells may not 
produce HSPG that are representative of those found in human cells. To address this, we 
expressed human Syndecan-1 in these cells, given the established ability of this HSPG to 
bind HGF.36 Once again, no evidence of CAR-mediated targeting of these cells was 
observed.  
Several explanations can be envisioned for the inability of GAGs or proteoglycans to 
promote the MET-independent activation of NK1-targeted CARs. First, while solid phase 
assays attributed high (nanomolar) affinity to GAG/ NK1 interactions,46 more recent studies 
suggest that when this interaction is studied in solution, the true Kd lies within the 
micromolar range.44, 45 The latter may be insufficient to promote the activation of CAR-
engineered T-cells. An alternative possibility stems from the fact that T-cells produce a range 
of GAGs and proteoglycans,47 especially when activated.48, 49 The predominant side chain is 
chondroitin sulfate, which has recently been shown to bind HGF.44  Consequently, the GAG 
binding site of the CAR may be saturated given the large local concentration of these 
potential binding partners, priming the receptor to engage in high affinity binding to MET 
alone. Lastly, it is possible that mutation of several lysine resides to glutamic acid in the 
engineered cM2.2rev variant reduce its binding affinity towards heparin. 
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Given the comparable in vitro anti-tumor activity of all three NK1-targeted 
candidates, one CAR was advanced to in vivo evaluation in tumor-bearing mice. These 
studies demonstrated that MET re-targeted CAR T-cells elicited the dose-dependent and 
progressive regression of an established mesothelioma tumor burden. A relatively high dose 
of 2.5 million CAR-engineered T-cells was required to control the REN xenograft, in keeping 
with its more modest expression of MET (Fig. 5A). While background alloreactivity was 
evident in these studies, significantly enhanced tumor control was observed with MET re-
targeted CAR T-cells. Although human HGF and NK1 are fully active on the mouse MET 
receptor,50 treatment was well tolerated without any weight loss or histologic evidence of 
end-organ toxicity. 
Our study is not the first to engineer a MET-specific CAR. Frigault et al. described a 
second generation candidate MET CAR in which targeting was achieved using an scFv 
isolated from the 5D5 hybridoma.42 This CAR exhibited constitutive activity leading to tonic 
signaling in T-cells, resulting in acquisition of an exhausted phenotype and compromised 
anti-tumor function. In this context, constitutive CAR activity has been ascribed to the 
propensity of some scFvs to undergo antigen-independent clustering,51 an attribute that would 
not occur using a ligand-based targeting moiety. Tonic signaling could be overcome by 
expression of the MET CAR at lower levels in the engineered T-cell population. However, 
anti-tumor activity of the resultant CAR T-cells was insignificantly improved, when 
compared to the alloreactive effect of CAR T-cells directed against an irrelevant antigen.42 
An important consideration is the expression of MET in numerous organs (e.g. lung, 
kidney, and liver), raising concerns that 'on target/off cancer' toxicity could compromise this 
therapeutic strategy. Four points are of relevance in the evaluation and mitigation of this risk. 
First, intra-tumoral delivery of CAR T-cells mediates therapeutic benefit in the absence of 
significant toxicity.52 In an ongoing clinical trial, we have shown that doses of up to 300 
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million ErbB re-targeted CAR T-cells can be delivered using the intra-tumoral route in 
patients with head and neck cancer, without dose-limiting toxicity or detectable systemic 
absorption of the T-cells.53 Second, intra-cavitary delivery of CAR T-cells is likely to also 
prove safer than their systemic administration. This is supported by the normal histologic 
analysis of MET-expressing mouse organs analyzed in this study, despite targeting of CARs 
with a ligand that is known to bind to the murine MET ortholog. Third, we are not the first 
group to demonstrate the safety of MET targeting using a directly cytolytic approach. A 
MET-specific monoclonal antibody that elicits potent antibody-dependent cell mediated 
cytotoxicity achieved anti-tumor activity combined with excellent safety when administered 
to cynomolgus monkeys, in which both target binding and Fc-mediated interactions are fully 
retained.54 Finally, should MET targeting prove unduly toxic despite the above 
considerations, combinatorial strategies in which optimal CAR T-cell activation is contingent 
upon co-engagement of MET and a second target may provide a strategy that more 
effectively balances efficacy with safety.55, 56 
In summary, data presented in this study demonstrate that MET can be effectively 
targeted using ligand-directed CAR T-cells. Clinical evaluation of MET re-targeted CAR T-
cells warrants consideration in this disease, using intra-cavitary delivery to maximize tumor 
delivery.14 Inclusion of a suicide gene (such as inducible caspase 9)57 would be recommended 
in such a protocol, as is currently under study with mesothelin-targeted CAR T-cells 
(https://clinicaltrials.gov/ct2/show/NCT02414269, accessed 07-15-2017). 
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MATERIALS AND METHODS 
 
All mandatory laboratory health and safety procedures have been complied with over the 
course of this work.  
 
DNA constructs 
All recombinant DNA constructs were expressed using the SFG retroviral vector. Codon 
optimized cDNAs encoding CAR targeting moieties were synthesized by Genscript. All 
contained an alanine codon after the start codon in order to preserve the Nco1 restriction site. 
Fragments were substituted by molecular cloning for the smaller Nco1/Not1 fragment within 
SFG T-28z (previously referred to as Tm28z).31 Codon optimized cDNAs encoding human 
MET, CD44v6 and Syndecan-1 were synthesized by Genscript and were cloned as Nco1/ 
Xho1 fragments in the SFG retroviral vector. The ffLuc/ RFP retroviral vector, C-28z control 
CAR (referred to previously as C20-28z) and IL-4 receptor-a/ IL2/15 receptor b chimeric 
cytokine receptor (4αβ) have all been previously described.31, 33  
 
Cell culture and gene transfer 
This study was approved by the South-East London Research Ethics Committee 1 (reference 
09/H0804/92). Peripheral blood T-cells from healthy donors were activated using 
CD3+CD28-coated paramagnetic beads and subjected to RetroNectin-enhanced retroviral-
mediated gene transfer and culture as described.31 Source and culture conditions for 
mesothelioma tumor cell lines have been described.15 T47D cells were obtained from the 
American Tissue Culture Collection while PC3 LN3 cells were provided by Prof Suzanne 
Eccles (Institute of Cancer Research, London, UK). Human tumor cell lines were subject to 
retroviral transduction using supernatant (0.44µM filtered) collected from PG13 retroviral 
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packaging cells while mouse target cells were transduced using supernatant collected from 
Phoenix Eco retroviral packaging cells (both obtained from the European Collection of 
Authenticated Cell Cultures). 
 
Immunohistochemistry of tumors 
Access to patient tissue samples and data is regulated under the Human Tissue Act and Guy’s 
and St Thomas’ Hospital Thoracic Cancer Biobank Access Committee (License number 
12121) in accordance with NHS Research Ethics Committee conditions. Mesothelioma tissue 
microarrays (TMAs) were acquired from the Departmental Tissue Bank. Sections (3µm) were 
cut from formalin fixed paraffin-embedded TMA blocks of 114 mesotheliomas obtained at 
video-associated thoracoscopic surgery or open pleural biopsy and were prepared on 
appropriately coated slides. Dewaxing and blockade of endogenous peroxidase were 
performed as previously described.15 Microarrays were processed using a Ventana 
Benchmark Ultra using methods recommended by the manufacturers. In brief, antigen was 
retrieved using Cell Conditioning solution 1 (Ventana). Slides were stained with CONFIRM 
anti-total c-MET (SP44) rabbit monoclonal antibody C-MET for 16 minutes at 37°C. 
Antibody binding was visualized using the Benchmark ultraView Universal DAB detection 
kit. Slides were lightly counterstained with hematoxylin. Breast carcinoma sections were 
used as positive and negative controls. For all negative controls, normal horse serum was 
used instead of primary antibody. Following staining, TMA slides were scored for intensity 
of staining by an independent histopathologist, who reported results as negative (absence of 
staining), low intensity (+), moderate intensity (++) or high intensity (+++).  
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Flow cytometry analysis 
Expression of CARs was detected using 9e10 hybridoma supernatant (generated in house) 
followed by PE-conjugated goat anti-mouse IgG (Dako), making comparison with cells 
incubated with secondary antibody alone. Expression of 4ab was detected using PE-
conjugated anti-CD124 (BD Pharmingen). Human MET and CD44v6 were detected using 
FITC-conjugated rat and mouse IgG1 antibodies respectively (eBioscience). Human 
Syndecan-1 was detected using APC-conjugated rat IgG1 anti-human CD138 (BioLegend). 
Heparan sulfate was detected using FITC-conjugated 10e4 (Stratech Scientific Ltd.). Isotype 
controls from the same supplier were used where indicated. Flow cytometry was performed 
using an LSRFortessa cytometer and analyzed with FloJo software. 
 
Western blotting 
CAR-transduced or unmodified control T-cells (0.5x107 cells) were lysed in RIPA buffer (50 
mM Tris, pH 7.5, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 
1% Triton X100, 1 mM phenylmethylsulfonyl fluoride) containing cOmplete protease 
inhibitor cocktail tablets (Roche) as per manufacturer’s instruction. Cell lysates were 
separated under denaturing conditions on a 4-20% gradient gel (Invitrogen), transferred to 
PVDF membrane (Amersham Biosciences) and probed with mouse anti-human CD3z 
antibody (BD Biosciences) followed by HRP-conjugated goat anti-mouse IgG (Dako) both 
diluted 1:1000 in TBS-Tween/5% skimmed milk. Bands were developed using an ECL 
Western Blotting Detection kit (Amersham Biosciences) according to manufacturer’s 
instruction.    
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Cytotoxicity, cytokine release and luciferase assays 
Target cells were plated overnight (either 2 x 104 cells in 96 well plates or 2 x 105 cells in 24 
well plates). Test or control T-cells were added on the next day at the specified ratio. Anti-
tumor activity was quantified by MTT assay, as described.31 Interferon (IFN)-γ and IL-2 was 
measured in supernatants collected after 48 hours using Ready Set Go ELISA kits 
(eBioscience), as per manufacturer’s protocol. In vitro luciferase testing of tumor cells was 
performed as described.31 A human cytokine antibody array was performed according to the 
manufacturer’s instructions (Abcam). 
 
Animal studies 
In vivo experimentation complied with UK Home Office guidelines, under project license 
70/7794. NOD SCID gc null mice were inoculated by i.p. injection with ffLuc/RFP+ REN 
cells. Tumor engraftment was confirmed by bioluminescence imaging (BLI) using the IVIS 
Lumina Imaging platform and Living Image software (PerkinElmer). Mice were sorted into 
groups with similar mean total flux BLI measurements. Treatment groups were assigned 
numbers and all treatment and imaging was carried out thereafter in a blinded fashion. 
Following i.p. delivery of CAR T-cells, tumor tracking was performed using BLI.58 Mice 
were culled when symptomatic due to disease progression, or when experimental endpoints 
had been met. 
 
Statistical analysis 
Analysis was performed using Excel for Mac 2011 (Berkshire, UK), GraphPad Prism 6.0, 
(GraphPad software) or IBM SPSS Statistics 22 for Mac. Comparison between groups was 
performed using one-way or two-way ANOVA, followed by Tukey’s multiple comparisons 
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test. For statistical comparison of two groups, datasets were analyzed by Student’s t test. 
Significance in Kaplan Meier curves was determined using the Log-rank (Mantel Cox) test. 
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FIGURE LEGENDS 
 
Figure 1. Histology, MET receptor expression and survival analysis of patients with 
malignant pleural mesothelioma. (A) Kaplan Meier plot for survival of patients with 
mesothelioma of the specified histologic subtypes. (B) Representative example of MET 
staining pattern seen in mesothelioma tissue microarray sections. Magnification x 200. (C) 
Kaplan Meier plots for survival of patients with mesothelioma according to level of 
expression of MET. p value was generated by Log-rank (Mantel Cox) test. 
 
Figure 2. Sequence and expression of candidate MET-specific CARs in human T-cells. 
(A) Targeting moieties were derived from the NK1 splice variant of HGF and contained the 
indicated mutations. Both M2.2 and cM2.2 contain a D127N revertant mutation which 
restores the naturally occurring sequence found in human NK1. (B) Cartoon structure of 
CARs. The horizontal line indicates the transmembrane domain. (C) Representative examples 
of cell surface expression of the indicated CARs. Detection was performed by flow 
cytometry after incubation with the anti-Myc 9e10 antibody. Percentage positivity has been 
calculated with respect to staining by secondary antibody alone. Data are representative of 10 
independent replicates. (D) Expression of CARs in human T-cells was also detected by 
western blotting, performed under reducing conditions and probed with an anti-CD3z 
antibody. Arrowed CAR bands are of the predicted molecular mass while the endogenous T-
cell receptor-associated CD3z band (predicted molecular mass 18kDa) serves as a loading 
control. 
 
Figure 3. Assessment of specificity of candidate MET targeted CARs using NIH3T3-
based artificial antigen presenting cells (AAPC) - I. (A) NIH3T3 fibroblasts were engineered 
	 27	
to express human MET, CD44v6 or both molecules. Expression was detected by flow 
cytometry. Percentage positivity has been calculated with respect to staining by an isotype 
control antibody. Data are representative of three independent experiments. (B) Transduction 
efficiency of human T-cells engineered to express the indicated candidate MET-specific 
CARs (1-28z, M-28z, cM-28z), control CARs targeted against ErbB dimers (T-28z) or 
control CAR targeted with a scrambled 20mer peptide (C-28z). (C)  CAR-engineered T-cells 
were co-cultivated with the indicated NIH3T3-based AAPC for 24 or 48 hours at the 
specified effector:target ratios. After removal of T-cells by careful washing with PBS, 
residual viability of NIH3T3 cells was determined by MTT assay, making comparison with a 
parallel culture of the corresponding NIH3T3 cells alone. (D) Interferon-g content of 
supernatants harvested from these co-cultures was quantified by ELISA. Data in (B)-(D) 
show mean + SD of 5 independent replicate experiments. *p<0.05; ** p<0.01; ***p<0.001, 
making comparison with untrans(duced) T-cells or, where indicated, between CAR T-cells 
under the appropriate horizontal line. 
 
Figure 4.  Assessment of specificity of candidate MET targeted CARs using NIH3T3-
based artificial antigen presenting cells (AAPC) - II. (A) NIH3T3 fibroblasts were engineered 
to express human MET or Syndecan-1. Expression was detected by flow cytometry. 
Percentage positivity has been calculated with respect to staining by an isotype control 
antibody. Data are representative of three independent experiments. (B) Transduction 
efficiency of human T-cells engineered to express the indicated candidate MET-specific 
CARs (1-28z, M-28z, cM-28z), control CARs targeted against ErbB dimers (T-28z) or 
control CAR targeted with a scrambled 20mer peptide (C-28z). (C) CAR-engineered T-cells 
were co-cultivated with the indicated NIH3T3-based AAPC for 24 or 48 hours at the 
specified effector:target ratios. After removal of T-cells by careful washing with PBS, 
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residual viability of NIH3T3 cells was determined by MTT assay, making comparison with a 
parallel culture of the corresponding NIH3T3 cells alone. Data in (B)-(C) show mean + SD of 
3 independent replicate experiments. ***p<0.001, making comparison with untrans(duced) 
T-cells. 
 
Figure 5. Characterization of human malignant pleural mesothelioma cell lines. The 
indicated human MPM cell lines were analyzed by flow cytometry for expression of MET 
(A), Syndecan-1 (B) or CD44v6 (C).  PC3 LN3 cells were employed as a positive control for 
MET and Syndecan-1 expression, while T47D cells were employed as a positive control for 
CD44v6 expression. Untransduced T-cells were also analyzed for expression of these 
molecules. Data are representative of three independent experiments, all of which yielded 
similar findings. 
 
Figure 6. In vitro cytotoxic activity of MET re-targeted CAR T-cells against malignant 
pleural mesothelioma cell lines. CAR engineered T-cells (transduction efficiency shown in 
A) were co-cultivated with malignant pleural mesothelioma cells for 48 hours at the indicated 
effector:target ratios. All CAR T-cells co-expressed the 4ab chimeric cytokine receptor. (B) 
After removal of T-cells, residual viable tumor was quantified by MTT assay, making 
comparison with a parallel culture of tumor cells alone (set to 100%). (C) Supernatants 
collected from these cultures were analyzed for interferon-g content. Data show mean + SD 
of 3 independent replicate experiments. *p<0.05; ** p<0.01; ***p<0.001, making 
comparison with untrans(duced) T-cells or, where indicated, between CAR T-cells under the 
appropriate horizontal line. 
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Figure 7. Ectopic over-expression of CD44v6 does not render mesothelioma tumor cells 
more amenable to destruction by MET re-targeted CAR T-cells. Mesothelioma tumor cell 
lines were engineered to over-express CD44v6 (v6). (A) Transduction efficiency of human T-
cells, engineered to express the indicated CARs. (B) CAR-engineered T-cells were co-
cultivated with unmodified or v6-engineered malignant pleural mesothelioma cells at a 1:1 
effector:target ratio and for the indicated interval. An MTT assay was performed after 72 
hours to quantify residual tumor cell viability. (C) Supernatants were harvested from these 
co-cultivations after 48 hours and were analyzed for interferon-g content by ELISA.  All data 
shown are mean + SD of three independent replicate experiments. *p<0.05; ** p<0.01; 
***p<0.001 making comparison with untrans(duced) T-cells.  
 
Figure 8. In vivo anti-tumor activity of MET re-targeted CAR T-cells against an 
established malignant pleural mesothelioma xenograft. (A) T-cells were engineered to 
express the indicated test (cM-28z) or control CAR (C-28z), co-expressed with 4ab. NOD 
SCID gc null mice were inoculated i.p. with 5 x 104 ffLuc/ RFP+ REN tumor cells. Following 
assignment to groups with comparable mean established tumor burden, mice were treated in a 
blinded fashion 7 days after tumor implantation (arrowed) with cM-28z+ or C-28z+ CAR T-
cells, administered to groups of 5 mice at (L)ow or (H)igh doses of 2.5 x 106 or 10 x 106 T-
cells respectively. Comparison was made with untrans(duced) T-cells (10 x 106 cells; n=5 
mice) or PBS (n=8 mice). Serial bioluminescence imaging of animals that received low dose 
(B) or high doses (C) of the indicated T-cell populations are shown. The PBS group is shown 
on each panel for reference. (D) Bioluminescence images of representative mice are shown 
on the same imaging scale (E) over the course of the experiment. (F) Serial weights of mice. 
All data are mean + SD of n=5-8 mice. *p<0.05; ** p<0.01 making comparison with PBS-
treated mice. 
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SUPPLEMENTARY FIGURE 1. Representative examples to indicate co-expression of 9e10 epitope-tagged
CARs and the 4ab chimeric cytokine receptor. Stoichiometric co-expression of transgenes was achieved using an
intervening Thosea Asigna 2A ribosomal skip peptide, inserted within the SFG retroviral vector.
33 26
50 37
10e4 (HSPG)                            
isotype
A
B
NIH3T3
T-cells
SUPPLEMENTARY FIGURE 2. Flow cytometric analysis of heparan sulfate proteoglycan (HSPG) expression
in NIH3T3 cells (A) and activated CAR T-cells (B) was performed using FITC-conjugated 10e4, making
comparison with an isotype matched control antibody. Data are representative of three independent replicate
experiments.
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SUPPLEMENTARY FIGURE 3. Flow cytometric analysis of heparan sulfate proteoglycan (HSPG) expression
in the indicated MPM tumor cell lines was performed using FITC-conjugated 10e4, making comparison with an
isotype matched control antibody. Data are representative of three independent replicate experiments.
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SUPPLEMENTARY FIGURE 4. Untrans(duced) or CAR engineered T-cells (transduction efficiency shown in
Fig. 3B) were co-cultivated with malignant pleural mesothelioma cells for 48 hours at the indicated effector:target
ratios. After 24 hours, supernatants were collected and the concentration of IL-2 was determined using ELISA. The
data presented have been compiled from 4-7 supernatant samples derived from three independent experiments and
are presented as mean ± SD. Significance was determined using the unpaired Student’s t-test: *p<0.05, **p<0.005
and ***p<0.0005.
Figure	S4
1-28z            
M-28z            
cM-28z            
C-28z            
Untrans.            
Key            
In
te
rle
uk
in
-2
 (p
g/
m
L)
H28
1:1             2:1 1:1             2:1
****
REN                                            
0
200
150
100
50
250
0
200
150
100
50
250
****
**
*
*
****
**
***
**
****
Effector: target ratio
SUPPLEMENTARY FIGURE 5. Untrans(duced) or CAR engineered T-cells (transduction efficiency shown in
Fig. 3B) were co-cultivated with REN mesothelioma cells. After 24 hours, supernatants were incubated on an
antibody array for the indicated cytokines and chemokines.
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SUPPLEMENTARY FIGURE 6. Time course of cytotoxicity mediated by MET re-targeted CAR T-cells against
mesothelioma tumor cells. 5 x 105 tumor cells were plated in duplicate overnight. 1 x 106 of the indicated CAR T-
cell populations were added to (A) H28, (B) REN, (C) Ju77, (D) LO68 or (E) PC3 LN3 tumor cell cultures. MTT
analysis was performed to determine tumor cell viability after 24, 48 and 72 hours (mean + SD). PC3 LN3 was used
as a MET-expressing positive control that is also amenable to destruction by T-28z+ T-cells. (F) Transduction
efficiencies of T-cells are indicated.
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Figure	S7
SUPPLEMENTARY FIGURE 7. Establishment of mesothelioma xenograft model. (A) REN tumor cells were
engineered to co-express tandem dimer tomato red fluorescent protein (RFP) and firefly luciferase (ffLuc) using a
Thosea Asigna 2A ribosomal skip peptide containing retroviral vector. (A) Cells were flow sorted based on RFP
expression and then analyzed by flow cytometry. (B) To establish a xenograft model, the indicated number of RFP/
ffLuc+ REN tumor cells were inoculated into NOD SCID gc null mice by i.p. injection. Serial bioluminescence
imaging was performed at the indicated intervals thereafter (C; mean + SD, n=3 mice per group).
99
